Inventor
DENG LIANG
US28 patents
⚠️ This page may combine multiple inventors who share the name “DENG LIANG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MEMORIAL SLOAN KETTERING CANCER CENTER
16 patentsUS10736962B2Aug 11, 2020
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER15 citations94
US10548930B2Feb 4, 2020
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER15 citations93
US10512662B2Dec 24, 2019
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER6 citations84
US10639366B2May 5, 2020
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER10 citations83
US10176292B2Jan 8, 2019
STING crystals and modulators
MEMORIAL SLOAN KETTERING CANCER CENTER7 citations82
US12036279B2Jul 16, 2024
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11986503B2May 21, 2024
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11541087B2Jan 3, 2023
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11285209B2Mar 29, 2022
Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER3 citations73
US10765711B2Sep 8, 2020
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER2 citations73
US11253560B2Feb 22, 2022
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER3 citations72
US12397029B2Aug 26, 2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations62
US11884939B2Jan 30, 2024
Vaccinia virus mutants useful for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations62
US11426460B2Aug 30, 2022
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations62
US11242509B2Feb 8, 2022
Vaccinia virus mutants useful for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations62
US12252702B2Mar 18, 2025
Recombinant poxviruses for cancer immunotherapy
MEMORIAL SLOAN KETTERING CANCER CENTER0 citations60
APPLE INC
7 patentsUS11270753B2Mar 8, 2022
Dynamic refresh rate control
APPLE INC3 citations72
US10978136B2Apr 13, 2021
Dynamic refresh rate control
APPLE INC3 citations72
US11594189B2Feb 28, 2023
Backlight reconstruction and compensation-based throttling
APPLE INC3 citations68
US11823728B2Nov 21, 2023
Dynamic refresh rate control
APPLE INC0 citations62
US10175905B2Jan 8, 2019
Systems and methods for dynamically switching memory performance states
APPLE INC1 citations60
US11842700B2Dec 12, 2023
Backlight reconstruction and compensation-based throttling
APPLE INC0 citations58
US9607586B2Mar 28, 2017
Asymmetric circuitry
APPLE INC0 citations42